Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials

Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption. Denosumab inhibits bone loss; therefore, it is used to treat metabolic bone disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Junjie, Hu, Desheng, Zhang, Yan, Ma, Chen, Shen, Lin, Shuai, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969102/
https://www.ncbi.nlm.nih.gov/pubmed/36860316
http://dx.doi.org/10.3389/fonc.2023.1133828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969102/
https://www.ncbi.nlm.nih.gov/pubmed/36860316
http://dx.doi.org/10.3389/fonc.2023.1133828

Ejemplares similares